Detalles de la búsqueda
1.
Outcomes by Candida spp. in the ReSTORE Phase 3 trial of rezafungin versus caspofungin for candidemia and/or invasive candidiasis.
Antimicrob Agents Chemother
; 68(5): e0158423, 2024 May 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-38526046
2.
Characterizing patients with rare mucormycosis infections using real-world data.
BMC Infect Dis
; 22(1): 154, 2022 Feb 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-35164701
3.
Clinical experience with isavuconazole in healthy volunteers and patients with invasive aspergillosis in China, and the results from an exposure-response analysis.
Mycoses
; 64(4): 445-456, 2021 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-33355949
4.
Evaluation of anidulafungin in the treatment of intra-abdominal candidiasis: a pooled analysis of patient-level data from 5 prospective studies.
Eur J Clin Microbiol Infect Dis
; 38(10): 1849-1856, 2019 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-31280481
5.
Utility of CT assessment in hematology patients with invasive aspergillosis: a post-hoc analysis of phase 3 data.
BMC Infect Dis
; 19(1): 471, 2019 May 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-31138134
6.
Efficacy and safety of combination antifungal therapy in Korean haematological patients with invasive aspergillosis.
Mycoses
; 62(10): 969-978, 2019 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-31355956
7.
Healthcare Resource Utilization and Discharge Readiness in Adult Hospitalized Patients With Candidemia or Invasive Candidiasis Who Received an Echinocandin: An Analysis of United States Hospitals.
Open Forum Infect Dis
; 11(1): ofad703, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-38213636
8.
Efficacy and safety of rezafungin and caspofungin in candidaemia and invasive candidiasis: pooled data from two prospective randomised controlled trials.
Lancet Infect Dis
; 24(3): 319-328, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-38008099
9.
Post-hoc analysis of the safety and efficacy of isavuconazole in older patients with invasive fungal disease from the VITAL and SECURE studies.
Sci Rep
; 13(1): 6730, 2023 04 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-37185921
10.
A plain language summary on preventing fungal infections with isavuconazole in people with blood-related conditions.
Future Microbiol
; 18: 861-866, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37641932
11.
Study of an antifungal medicine isavuconazole used in treatment of mold infections in China: A plain language summary.
Future Microbiol
; 18: 87-91, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36511165
12.
Tissue distribution of anidulafungin in neonatal rats.
Birth Defects Res B Dev Reprod Toxicol
; 95(1): 89-94, 2012 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-22311649
13.
Risk factors in people with mold infections that have spread to different parts of the body: a plain language summary.
Future Microbiol
; 17: 1271-1275, 2022 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-36043988
14.
Effectiveness and safety of isavuconazole prophylaxis for invasive fungal infections in the haematologic setting.
Hematology
; 27(1): 723-732, 2022 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-35688453
15.
Plain language summary: use of isavuconazole in Chinese patients with an invasive fungal disease.
Future Microbiol
; 17: 1203-1206, 2022 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-35916057
16.
In vitro Activity of Isavuconazole and Comparators Against Clinical Isolates of Molds from a Multicenter Study in China.
Infect Drug Resist
; 15: 2101-2113, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35498631
17.
Invasive Candidiasis in Patients with Solid Tumors Treated with Anidulafungin: A Post Hoc Analysis of Efficacy and Safety of Six Pooled Studies.
Clin Drug Investig
; 41(6): 539-548, 2021 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-33891293
18.
Patient Characteristics and Risk Factors in Invasive Mold Infections: Comparison from a Systematic Review and Database Analysis.
Clinicoecon Outcomes Res
; 13: 593-602, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34211287
19.
Safety, Efficacy and Pharmacokinetics of Anidulafungin in Patients 1 Month to <2 Years of Age With Invasive Candidiasis, Including Candidemia.
Pediatr Infect Dis J
; 39(4): 305-309, 2020 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-32032174
20.
Evaluation of the Effectiveness of Additional Risk Minimization Measures for Voriconazole in the EU: Findings and Lessons Learned from a Healthcare Professional Survey.
Pharmaceut Med
; 33(2): 121-133, 2019 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-31933256